Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 37 entries
Sorted by: Best Match Show Resources per page
Macrophages at work: phagocytosis of urinary fungi.

Clinical kidney journal

Tesser Poloni JA, Perazella MA, Neild GH.
PMID: 26019856
Clin Kidney J. 2013 Apr;6(2):233-4. doi: 10.1093/ckj/sfs184. Epub 2013 Feb 03.

No abstract available.

Cite
Tesser Poloni JA, Perazella MA, Neild GH. Macrophages at work: phagocytosis of urinary fungi. Clin Kidney J. 2013;6(2):233-4doi: 10.1093/ckj/sfs184.
Tesser Poloni, J. A., Perazella, M. A., & Neild, G. H. (2013). Macrophages at work: phagocytosis of urinary fungi. Clinical kidney journal, 6(2), 233-4. https://doi.org/10.1093/ckj/sfs184
Tesser Poloni, José Antonio, et al. "Macrophages at work: phagocytosis of urinary fungi." Clinical kidney journal vol. 6,2 (2013): 233-4. doi: https://doi.org/10.1093/ckj/sfs184
Tesser Poloni JA, Perazella MA, Neild GH. Macrophages at work: phagocytosis of urinary fungi. Clin Kidney J. 2013 Apr;6(2):233-4. doi: 10.1093/ckj/sfs184. Epub 2013 Feb 03. PMID: 26019856; PMCID: PMC4432439.
Copy Download .nbib Format: NLM
The role of mast cells in AIN: friend, foe, bystander, or all of the above?.

Clinical nephrology

Perazella MA.
PMID: 26296036
Clin Nephrol. 2015 Sep;84(3):123-6. doi: 10.5414/cnp84123.

No abstract available.

Cite
Perazella MA. The role of mast cells in AIN: friend, foe, bystander, or all of the above?. Clin Nephrol. 2015;84(3):123-6doi: 10.5414/cnp84123.
Perazella, M. A. (2015). The role of mast cells in AIN: friend, foe, bystander, or all of the above?. Clinical nephrology, 84(3), 123-6. https://doi.org/10.5414/cnp84123
Perazella, Mark A. "The role of mast cells in AIN: friend, foe, bystander, or all of the above?." Clinical nephrology vol. 84,3 (2015): 123-6. doi: https://doi.org/10.5414/cnp84123
Perazella MA. The role of mast cells in AIN: friend, foe, bystander, or all of the above?. Clin Nephrol. 2015 Sep;84(3):123-6. doi: 10.5414/cnp84123. PMID: 26296036.
Copy Download .nbib Format: NLM
Nephrotoxicity of HAART.

AIDS research and treatment

Kalyesubula R, Perazella MA.
PMID: 21860787
AIDS Res Treat. 2011;2011:562790. doi: 10.1155/2011/562790. Epub 2011 Aug 15.

Highly active antiretroviral therapy (HAART) and other medical therapies for HIV-related infections have been associated with toxicities. Antiretroviral therapy can contribute to renal dysfunction directly by inducing acute tubular necrosis, acute interstitial nephritis, crystal nephropathy, and renal tubular disorders...

Cite
Kalyesubula R, Perazella MA. Nephrotoxicity of HAART. AIDS Res Treat. 2011;2011:562790doi: 10.1155/2011/562790.
Kalyesubula, R., & Perazella, M. A. (2011). Nephrotoxicity of HAART. AIDS research and treatment, 2011562790. https://doi.org/10.1155/2011/562790
Kalyesubula, Robert, and Perazella, Mark A. "Nephrotoxicity of HAART." AIDS research and treatment vol. 2011 (2011): 562790. doi: https://doi.org/10.1155/2011/562790
Kalyesubula R, Perazella MA. Nephrotoxicity of HAART. AIDS Res Treat. 2011;2011:562790. doi: 10.1155/2011/562790. Epub 2011 Aug 15. PMID: 21860787; PMCID: PMC3157198.
Copy Download .nbib Format: NLM
Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events.

Kidney international reports

Herrmann SM, Perazella MA.
PMID: 32775813
Kidney Int Rep. 2020 Apr 29;5(8):1139-1148. doi: 10.1016/j.ekir.2020.04.018. eCollection 2020 Aug.

Renal toxicities have been increasingly recognized as complications of the immune checkpoint inhibitors (ICIs). Recent studies have outlined the incidence and potential risk factors for nephrotoxicity. For clinicians, the key question is how to manage patients who develop these...

Cite
Herrmann SM, Perazella MA. Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events. Kidney Int Rep. 2020;5(8):1139-1148doi: 10.1016/j.ekir.2020.04.018.
Herrmann, S. M., & Perazella, M. A. (2020). Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events. Kidney international reports, 5(8), 1139-1148. https://doi.org/10.1016/j.ekir.2020.04.018
Herrmann, Sandra M, and Perazella, Mark A. "Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events." Kidney international reports vol. 5,8 (2020): 1139-1148. doi: https://doi.org/10.1016/j.ekir.2020.04.018
Herrmann SM, Perazella MA. Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events. Kidney Int Rep. 2020 Apr 29;5(8):1139-1148. doi: 10.1016/j.ekir.2020.04.018. eCollection 2020 Aug. PMID: 32775813; PMCID: PMC7403510.
Copy Download .nbib Format: NLM
In Reply to 'Contrast-Enhanced CT in Patients With Kidney Disease: Some Considerations in Response to the ACR/NKF Consensus'.

Kidney medicine

Perazella MA, Weinreb JC, Davenport MS.
PMID: 32775994
Kidney Med. 2020 Jun 30;2(4):501. doi: 10.1016/j.xkme.2020.06.002. eCollection 2020.

No abstract available.

Cite
Perazella MA, Weinreb JC, Davenport MS. In Reply to 'Contrast-Enhanced CT in Patients With Kidney Disease: Some Considerations in Response to the ACR/NKF Consensus'. Kidney Med. 2020;2(4):501doi: 10.1016/j.xkme.2020.06.002.
Perazella, M. A., Weinreb, J. C., & Davenport, M. S. (2020). In Reply to 'Contrast-Enhanced CT in Patients With Kidney Disease: Some Considerations in Response to the ACR/NKF Consensus'. Kidney medicine, 2(4), 501. https://doi.org/10.1016/j.xkme.2020.06.002
Perazella, Mark A, et al. "In Reply to 'Contrast-Enhanced CT in Patients With Kidney Disease: Some Considerations in Response to the ACR/NKF Consensus'." Kidney medicine vol. 2,4 (2020): 501. doi: https://doi.org/10.1016/j.xkme.2020.06.002
Perazella MA, Weinreb JC, Davenport MS. In Reply to 'Contrast-Enhanced CT in Patients With Kidney Disease: Some Considerations in Response to the ACR/NKF Consensus'. Kidney Med. 2020 Jun 30;2(4):501. doi: 10.1016/j.xkme.2020.06.002. eCollection 2020. PMID: 32775994; PMCID: PMC7406849.
Copy Download .nbib Format: NLM
Inflammasome activation in neutrophils of patients with severe COVID-19.

Blood advances

Aymonnier K, Ng J, Fredenburgh LE, Zambrano-Vera K, Münzer P, Gutch S, Fukui S, Desjardins M, Subramaniam M, Baron R, Raby BA, Perrella MA, Lederer JA, Wagner DD.
PMID: 34991159
Blood Adv. 2022 Jan 06; doi: 10.1182/bloodadvances.2021005949. Epub 2022 Jan 06.

Infection by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) engages the inflammasome in monocytes and macrophages and leads to the cytokine storm in COVID-19. Neutrophils, the most abundant leukocytes, release neutrophil extracellular traps (NETs), which have been implicated...

Cite
Aymonnier K, Ng J, Fredenburgh LE, et al. Inflammasome activation in neutrophils of patients with severe COVID-19. Blood Adv. 2022;doi: 10.1182/bloodadvances.2021005949.
Aymonnier, K., Ng, J., Fredenburgh, L. E., Zambrano-Vera, K., Münzer, P., Gutch, S., Fukui, S., Desjardins, M., Subramaniam, M., Baron, R., Raby, B. A., Perrella, M. A., Lederer, J. A., & Wagner, D. D. (2022). Inflammasome activation in neutrophils of patients with severe COVID-19. Blood advances, . https://doi.org/10.1182/bloodadvances.2021005949
Aymonnier, Karen, et al. "Inflammasome activation in neutrophils of patients with severe COVID-19." Blood advances vol. (2022). doi: https://doi.org/10.1182/bloodadvances.2021005949
Aymonnier K, Ng J, Fredenburgh LE, Zambrano-Vera K, Münzer P, Gutch S, Fukui S, Desjardins M, Subramaniam M, Baron R, Raby BA, Perrella MA, Lederer JA, Wagner DD. Inflammasome activation in neutrophils of patients with severe COVID-19. Blood Adv. 2022 Jan 06; doi: 10.1182/bloodadvances.2021005949. Epub 2022 Jan 06. PMID: 34991159; PMCID: PMC8741335.
Copy Download .nbib Format: NLM
Inflammasome activation in neutrophils of patients with severe COVID-19.

Blood advances

Aymonnier K, Ng J, Fredenburgh LE, Zambrano-Vera K, Münzer P, Gutch S, Fukui S, Desjardins M, Subramaniam M, Baron R, Raby BA, Perrella MA, Lederer JA, Wagner DD.
PMID: 34991159
Blood Adv. 2022 Jan 06; doi: 10.1182/bloodadvances.2021005949. Epub 2022 Jan 06.

Infection by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) engages the inflammasome in monocytes and macrophages and leads to the cytokine storm in COVID-19. Neutrophils, the most abundant leukocytes, release neutrophil extracellular traps (NETs), which have been implicated...

Cite
Aymonnier K, Ng J, Fredenburgh LE, et al. Inflammasome activation in neutrophils of patients with severe COVID-19. Blood Adv. 2022;doi: 10.1182/bloodadvances.2021005949.
Aymonnier, K., Ng, J., Fredenburgh, L. E., Zambrano-Vera, K., Münzer, P., Gutch, S., Fukui, S., Desjardins, M., Subramaniam, M., Baron, R., Raby, B. A., Perrella, M. A., Lederer, J. A., & Wagner, D. D. (2022). Inflammasome activation in neutrophils of patients with severe COVID-19. Blood advances, . https://doi.org/10.1182/bloodadvances.2021005949
Aymonnier, Karen, et al. "Inflammasome activation in neutrophils of patients with severe COVID-19." Blood advances vol. (2022). doi: https://doi.org/10.1182/bloodadvances.2021005949
Aymonnier K, Ng J, Fredenburgh LE, Zambrano-Vera K, Münzer P, Gutch S, Fukui S, Desjardins M, Subramaniam M, Baron R, Raby BA, Perrella MA, Lederer JA, Wagner DD. Inflammasome activation in neutrophils of patients with severe COVID-19. Blood Adv. 2022 Jan 06; doi: 10.1182/bloodadvances.2021005949. Epub 2022 Jan 06. PMID: 34991159.
Copy Download .nbib Format: NLM
Pharmacology behind Common Drug Nephrotoxicities.

Clinical journal of the American Society of Nephrology : CJASN

Perazella MA.
PMID: 29622670
Clin J Am Soc Nephrol. 2018 Dec 07;13(12):1897-1908. doi: 10.2215/CJN.00150118. Epub 2018 Apr 05.

Patients are exposed to numerous prescribed and over-the-counter medications. Unfortunately, drugs remain a relatively common cause of acute and chronic kidney injury. A combination of factors including the innate nephrotoxicity of drugs, underlying patient characteristics that increase their risk...

Cite
Perazella MA. Pharmacology behind Common Drug Nephrotoxicities. Clin J Am Soc Nephrol. 2018;13(12):1897-1908doi: 10.2215/CJN.00150118.
Perazella, M. A. (2018). Pharmacology behind Common Drug Nephrotoxicities. Clinical journal of the American Society of Nephrology : CJASN, 13(12), 1897-1908. https://doi.org/10.2215/CJN.00150118
Perazella, Mark A. "Pharmacology behind Common Drug Nephrotoxicities." Clinical journal of the American Society of Nephrology : CJASN vol. 13,12 (2018): 1897-1908. doi: https://doi.org/10.2215/CJN.00150118
Perazella MA. Pharmacology behind Common Drug Nephrotoxicities. Clin J Am Soc Nephrol. 2018 Dec 07;13(12):1897-1908. doi: 10.2215/CJN.00150118. Epub 2018 Apr 05. PMID: 29622670; PMCID: PMC6302342.
Copy Download .nbib Format: NLM
Introduction to Nephropharmacology for the Clinician: A New .

Clinical journal of the American Society of Nephrology : CJASN

Nolin TD, Perazella MA.
PMID: 29661769
Clin J Am Soc Nephrol. 2018 Jul 06;13(7):1083-1084. doi: 10.2215/CJN.03180318. Epub 2018 Apr 16.

No abstract available.

Cite
Nolin TD, Perazella MA. Introduction to Nephropharmacology for the Clinician: A New . Clin J Am Soc Nephrol. 2018;13(7):1083-1084doi: 10.2215/CJN.03180318.
Nolin, T. D., & Perazella, M. A. (2018). Introduction to Nephropharmacology for the Clinician: A New . Clinical journal of the American Society of Nephrology : CJASN, 13(7), 1083-1084. https://doi.org/10.2215/CJN.03180318
Nolin, Thomas D, and Perazella, Mark A. "Introduction to Nephropharmacology for the Clinician: A New ." Clinical journal of the American Society of Nephrology : CJASN vol. 13,7 (2018): 1083-1084. doi: https://doi.org/10.2215/CJN.03180318
Nolin TD, Perazella MA. Introduction to Nephropharmacology for the Clinician: A New . Clin J Am Soc Nephrol. 2018 Jul 06;13(7):1083-1084. doi: 10.2215/CJN.03180318. Epub 2018 Apr 16. PMID: 29661769; PMCID: PMC6032583.
Copy Download .nbib Format: NLM
Mesenchymal stromal cell-derived syndecan-2 regulates the immune response during sepsis to foster bacterial clearance and resolution of inflammation.

The FEBS journal

Han J, Shi Y, Willis G, Imani J, Kwon MY, Li G, Ayaub E, Ghanta S, Ng J, Hwang N, Tsoyi K, El-Chemaly S, Kourembanas S, Mitsialis SA, Rosas IO, Liu X, Perrella MA.
PMID: 34355516
FEBS J. 2021 Aug 06; doi: 10.1111/febs.16154. Epub 2021 Aug 06.

Sepsis is a life-threatening process related to a dysregulated host response to an underlying infection, which results in organ dysfunction and poor outcomes. Therapeutic strategies using mesenchymal stromal cells (MSCs) are under investigation for sepsis, with efforts to improve...

Cite
Han J, Shi Y, Willis G, et al. Mesenchymal stromal cell-derived syndecan-2 regulates the immune response during sepsis to foster bacterial clearance and resolution of inflammation. FEBS J. 2021;doi: 10.1111/febs.16154.
Han, J., Shi, Y., Willis, G., Imani, J., Kwon, M. Y., Li, G., Ayaub, E., Ghanta, S., Ng, J., Hwang, N., Tsoyi, K., El-Chemaly, S., Kourembanas, S., Mitsialis, S. A., Rosas, I. O., Liu, X., & Perrella, M. A. (2021). Mesenchymal stromal cell-derived syndecan-2 regulates the immune response during sepsis to foster bacterial clearance and resolution of inflammation. The FEBS journal, . https://doi.org/10.1111/febs.16154
Han, Junwen, et al. "Mesenchymal stromal cell-derived syndecan-2 regulates the immune response during sepsis to foster bacterial clearance and resolution of inflammation." The FEBS journal vol. (2021). doi: https://doi.org/10.1111/febs.16154
Han J, Shi Y, Willis G, Imani J, Kwon MY, Li G, Ayaub E, Ghanta S, Ng J, Hwang N, Tsoyi K, El-Chemaly S, Kourembanas S, Mitsialis SA, Rosas IO, Liu X, Perrella MA. Mesenchymal stromal cell-derived syndecan-2 regulates the immune response during sepsis to foster bacterial clearance and resolution of inflammation. FEBS J. 2021 Aug 06; doi: 10.1111/febs.16154. Epub 2021 Aug 06. PMID: 34355516.
Copy Download .nbib Format: NLM
Blocking hyaluronan synthesis alleviates acute lung allograft rejection.

JCI insight

Imani J, Liu K, Cui Y, Assaker JP, Han J, Ghosh AJ, Ng J, Shrestha S, Lamattina AM, Louis PH, Hentschel A, Esposito AJ, Rosas IO, Liu X, Perrella MA, Azzi J, Visner G, El-Chemaly S.
PMID: 34665782
JCI Insight. 2021 Nov 22;6(22). doi: 10.1172/jci.insight.142217.

Lung allograft rejection results in the accumulation of low-molecular weight hyaluronic acid (LMW-HA), which further propagates inflammation and tissue injury. We have previously shown that therapeutic lymphangiogenesis in a murine model of lung allograft rejection reduced tissue LMW-HA and...

Cite
Imani J, Liu K, Cui Y, et al. Blocking hyaluronan synthesis alleviates acute lung allograft rejection. JCI Insight. 2021;6(22)doi: 10.1172/jci.insight.142217.
Imani, J., Liu, K., Cui, Y., Assaker, J. P., Han, J., Ghosh, A. J., Ng, J., Shrestha, S., Lamattina, A. M., Louis, P. H., Hentschel, A., Esposito, A. J., Rosas, I. O., Liu, X., Perrella, M. A., Azzi, J., Visner, G., & El-Chemaly, S. (2021). Blocking hyaluronan synthesis alleviates acute lung allograft rejection. JCI insight, 6(22), . https://doi.org/10.1172/jci.insight.142217
Imani, Jewel, et al. "Blocking hyaluronan synthesis alleviates acute lung allograft rejection." JCI insight vol. 6,22 (2021). doi: https://doi.org/10.1172/jci.insight.142217
Imani J, Liu K, Cui Y, Assaker JP, Han J, Ghosh AJ, Ng J, Shrestha S, Lamattina AM, Louis PH, Hentschel A, Esposito AJ, Rosas IO, Liu X, Perrella MA, Azzi J, Visner G, El-Chemaly S. Blocking hyaluronan synthesis alleviates acute lung allograft rejection. JCI Insight. 2021 Nov 22;6(22). doi: 10.1172/jci.insight.142217. PMID: 34665782; PMCID: PMC8663774.
Copy Download .nbib Format: NLM
Blocking hyaluronan synthesis alleviates acute lung allograft rejection.

JCI insight

Imani J, Liu K, Cui Y, Assaker JP, Han J, Ghosh AJ, Ng J, Shrestha S, Lamattina AM, Louis PH, Hentschel A, Esposito AJ, Rosas IO, Liu X, Perrella MA, Azzi J, Visner G, El-Chemaly S.
PMID: 34665782
JCI Insight. 2021 Nov 22;6(22). doi: 10.1172/jci.insight.142217.

Lung allograft rejection results in the accumulation of low-molecular weight hyaluronic acid (LMW-HA), which further propagates inflammation and tissue injury. We have previously shown that therapeutic lymphangiogenesis in a murine model of lung allograft rejection reduced tissue LMW-HA and...

Cite
Imani J, Liu K, Cui Y, et al. Blocking hyaluronan synthesis alleviates acute lung allograft rejection. JCI Insight. 2021;6(22)doi: 10.1172/jci.insight.142217.
Imani, J., Liu, K., Cui, Y., Assaker, J. P., Han, J., Ghosh, A. J., Ng, J., Shrestha, S., Lamattina, A. M., Louis, P. H., Hentschel, A., Esposito, A. J., Rosas, I. O., Liu, X., Perrella, M. A., Azzi, J., Visner, G., & El-Chemaly, S. (2021). Blocking hyaluronan synthesis alleviates acute lung allograft rejection. JCI insight, 6(22), . https://doi.org/10.1172/jci.insight.142217
Imani, Jewel, et al. "Blocking hyaluronan synthesis alleviates acute lung allograft rejection." JCI insight vol. 6,22 (2021). doi: https://doi.org/10.1172/jci.insight.142217
Imani J, Liu K, Cui Y, Assaker JP, Han J, Ghosh AJ, Ng J, Shrestha S, Lamattina AM, Louis PH, Hentschel A, Esposito AJ, Rosas IO, Liu X, Perrella MA, Azzi J, Visner G, El-Chemaly S. Blocking hyaluronan synthesis alleviates acute lung allograft rejection. JCI Insight. 2021 Nov 22;6(22). doi: 10.1172/jci.insight.142217. PMID: 34665782.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 37 entries